## FORM 4

\_\_ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response. . . 0.5

1. Name and Address of Reporting Person *  Manak Mark M. (Last) (First) (Middle)  200 Stanley Plaza (Street)  Laurel MD 20707 (City) (State) (Zip)  2. Issuer Nameand Tic or Trading Symbol  Boston Biomedica, (BBII)  3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary)	4. Statement for (Month/Day/Year)  February/20/2003	6. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner X_ Officer (give title below) Other (specify below)  Senior Vice President, General Manager  7. Individual or Joint/Group Filing (Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person
--	---	---

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of	2. Transaction	2A. Deemed Execution Date, if any	3. Transactio (Instr. 8)		4. Securities A (Instr. 3, 4 and		Disposed of (D)	Owned	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial
Security	(Month/Day/	(Month/Day/								Ownership
(Instr. 3)	Year)	Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	(Instr. 4)	(Instr. 4)
Common Stock	02/20/03		M		519	A	\$2.006	23,989	D	
								4,000	I	Daughter

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

				4. Transac Code (Instr. 8		5. Number Derivative Securities Acquired Disposed (Instr. 3, 4	(A) or of (D)	6. Date Exer Expiration I (Month/Day	Date	7. Title and of Underlyi Securities (Instr. 3 and	ng		9. Number of Derivative Securities Beneficially	10. Ownership Form of	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/ Year)	3A. Deemed Execution Date, if any (Month/Day/ Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)	Owned Following	Derivative Securities: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option (Right to Buy)	\$3.25							02/28/97 (1)	2/28/06	Common Stock	2,500		2,500		
Option (Right to Buy)	\$3.25							04/14/99 (1)	04/14/08	Common Stock	6,000		6,000		
Option (Right to Buy)	\$4.00							02/03/01 (1)	02/03/10	Common Stock	5,000		5,000		
Option (Right to Buy)	\$3.08							02/11/03 (1)	02/11/12	Common Stock	11,500		11,500		
Option (Right to Buy)	\$2.70							12/02/03 (1)	12/02/12	Common Stock	35,000		35,000		
										Total	60,000		60,000	D	
					$\overline{\Box}$										

Explanation of Responses:

(1) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7. The options become exercisable in 25 percent annual increments beginning on the date set forth in Table II, Column 6.

/s/ Mark M. Manak
\*\* Signature of Reporting Person

02/25/03

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

http://www.sec.gov/divisions/corpfin/forms/form4.htm

Last update: 09/05/2002